Introduction
Hepatocellular carcinoma (HCC), one of the ten most frequent cancers world-wide, is associated with well de®ned viral and non-viral etiological factors. Chronic infection with hepatitis B (HBV) and hepatitis C (HCV) viruses, and oral intake of a¯atoxins are the major causes of HCC, but the molecular mechanisms underlying the malignant transformation of hepatocytes are largely unknown (Ozturk, 1995) . Long latent period (20 ± 30 years) between viral infections and the development of HCC suggests the multi-step nature of hepatocarcinogenesis (Ozturk, 1995) . Genetic studies provide sucient evidence for this hypothesis. Allelotype studies indicate that many chromosomal regions (i.e. 1p, 1q, 4q, 5q, 6q, 8p, 8q, 9p, 10q, 11p, 13q, 14q, 16p, 16q, 17p) undergo structural changes in HCC (Nagai et al., 1997; Piao et al., 1998 ; for review see Grisham, 1996) . Some of these chromosomal changes are associated with dierent tumour stages, suggesting that they are associated with the tumour progression (Tsuda et al., 1990) . The critical genes located at these chromosomal regions are mostly unknown. To date only a few genes including p53, p16, mannose-6-phosphate/insulin-like growth factor II receptor (M6P/IGFIIR), b-catenin (Miyoshi et al., 1998; De la Coste et al., 1998) and cyclin D have been shown to be signi®cantly altered in HCC (for review see Grisham, 1996) . Both the suspected genetic heterogeneity of HCC and the discordance between allelotype and mutation studies strongly suggest that many other genes undergo somatic mutations in these tumours.
Genes encoding for proteins involved in the control of hepatocyte growth (i.e. inhibitors of hepatocyte proliferation and the activators of apoptotic cell death) are potential tumour suppressor genes for HCC. Transforming growth factor-b (TGF-b) and activin are potent inhibitors of hepatocyte growth (Fausto et al., 1995) . TGF-b is also known to induce apoptosis in both hepatocytes and HCC cell lines (Oberhammer et al., 1992; Gressner et al., 1997) . Certain transformed cells, however, show defective response to TGF-binduced growth inhibition including some liver-derived cell lines (Fynan and Reiss, 1993) . Based on these observations, genes involved in TGFb signalling pathway are candidate tumour suppressor genes in HCC. For instance, M6P/IGFIIR gene was shown to be mutated in about 25% of HCCs displaying LOH at the M6P/IGFIIR locus (De Souza et al., 1995) . Although the protein product of this gene has a broad range of cellular functions, it is suspected to be an activator of latent TGF-b in the liver. In addition, at least two other genes involved in HCC, namely cyclin D and c-myc genes appear to be among the ultimate targets of TGFb signalling pathway, as their expression level is modi®ed following treatment of dierent cell lines with TGFb (Alexandrow and Moses, 1995 , Grisham, 1996 .
Recently, the Smad family of proteins have been discovered as mediators of TGFb signalling pathway. Eight distinct members of Smad family have been identi®ed in vertebrates and at least two of them, namely Smad2 and Smad4 act as tumour suppressor genes in humans (Heldin et al., 1997; Baker and Harland, 1997) . Smad4 and Smad2 are both involved in cytoplasmic signal transduction upon activation of TGF-b and activin receptors by their speci®c ligands (for review see Heldin et al., 1997) . Missense mutations within carboxyl terminal eector domains of Smad2 and Smad4 have been identi®ed in dierent cancers including the cancers of pancreas Moskaluk et al., 1997) , biliary tract (Hahn et al., 1998) , colon (Eppert et al., 1996; Riggins et al., 1996; Takagi et al., 1996) , lung (Uchida et al., 1996) , as well as head and neck carcinomas . Smad2 and Smad4 appear to be the most critical targets of mutational inactivation because a study based on 167 tumour samples suggested that mutational inactivation of the other Smad genes does not account for the widespread resistance of cancer cells to TGF-b (Riggins et al., 1997) . Based on these indications, we selected Smad2 and Smad4 (also called JV18-1 and DPC4 respectively) as candidate tumour suppressor genes in HCC and studied 35 primary tumours as well as six hepatoma cell lines for possible mutations. We demonstrate that both genes display somatic mutations in HCC, but the mutation frequency is low. We will discuss possible implications of these observations in relation with the role of TGFb signalling pathway in hepatocellular carcinogenesis.
Results and Discussion
To investigate the potential involvement of the Smad2 and Smad4 genes in HCCs, we screened 35 HCC samples as well as six hepatoma cell lines for possible genetic alterations of these genes. Initially, six hepatoma cell lines were tested by RT ± PCR for the expression of Smad2 and Smad4 genes. All cell lines expressed both Smad2 and Smad4 genes and RT ± PCR products did not show size alteration in the respective coding region (data not shown). Homozygous and large deletions of Smad2 and Smad4 genes have been reported for other cancers , Riggins et al., 1996 . But the hepatoma cell lines tested here did not show such alterations.
Next, we studied genomic DNA from 35 primary tumours. The majority of the previously identi®ed Smad2 and Smad4 gene mutations are located within the region coding for the highly conserved carboxyl terminal domains, corresponding to exon 8 ± 11 of both genes Riggins et al., 1996; Schutte et al., 1996 , Hahn et al., 1998 . In addition, two mutations, one located in exon 4 of Smad2 and another located in exon 2 of Smad4 aecting the Nterminal regions of Smad2 and Smad4 (Arg133Cys and Arg100Thr, respectively) proteins have been described in colon and pancreas cancers Shi et al., 1997) . To test whether HCCs display similar mutations, we studied exon 4 of Smad2, exon 2 of Smad4, in addition to exons 8 ± 11 of both genes by SSCP analysis. A total of seven HCC samples showed altered migration pattern (see Figure 1 for exon 8 alterations as an example). Four of these alterations (three in exon 8 and one in exon 10 of Smad4 gene) were also present in the non-tumour liver samples of the respective patients. DNA sequence analysis of these four tumours did not reveal any alteration in exonic sequences and immediately¯anking intronic regions (data not shown) suggesting that constitutional polymorphisms aecting intronic sequences were present in these patients. The other three SSCP alterations were seen only in tumour DNA, but not in non tumorous liver DNA. Sequence analysis of tumour and non-tumour liver DNA samples from All three of these somatic mutations were novel and have not been described previously. They all appear to be deleterious mutations because of the strong side chain charge changes in the replaced amino acid residues resulting from each mutation. Crystal structure of C-terminal domain of Smad4 reveals that Asp 332 residue is located in the trimeric interface region and forms a hydrogen bond with His 371 (Shi et al., 1997) . Because this interface region is crucial for trimeric complex formation, it is likely that Asp332Gly change, breaking the hydrogen bond, blocks the TGFb signal by preventing trimer formation of Smad4 protein. The Cys401 residue of Smad4 is highly conserved between Smad family members. This residue is located within the b6 sheet which makes the hydrophobic core, the b sandwich of Smad4 protein.
Amino acid change from cysteine to arginine will most probably aect Smad4 protein function by changing the conformation of the b sandwich. Gln407 of Smad2 is located in a region that is homologous to H4 helix domain of Smad4, also in trimeric interface region (Shi et al., 1997) .
All three mutations are located in the MH2 domain of Smad proteins. These proteins consist of three structurally and functionally distinct domains. The amino and carboxyl terminal regions of Smad proteins are referred to as MH1 and MH2 domains, respectively. The central region serves as a linker domain between MH1 and MH2 domains. The MH2 domain of Smad 1, 2 and 3 mediates homomeric interactions and is responsible for heteromeric interactions with Smad4. The MH2 domain also called eector domain is able to mimic the activity of the full length proteins (Heldin et al., 1997) . Thus it is very likely that the three mutations described here are not random mutations and that they either aect protein-protein interactions or destabilise the whole structure of the protein. Taken together, all three mutations described here appear to be deleterious mutations which may aect TGFb signalling pathway in these tumours.
The tumours described here have been previously examined for the presence of p53 gene mutations and HBV DNA (Unsal et al., 1994) . As shown in Table 1 , HBV DNA was present in all three tumours with Smad mutations. p53 was mutant (Arg249Ser) in T37 but not in two other tumours. Thus, it appears that Smad mutations described here are associated with HBV infection and that there appears to be no correlation with p53 mutations. On the other hand, it is noteworthy that all three mutations described here aected A:T pairs with a consistent change to G:C pairs. This pattern was recently shown to be a common type of mitochondrial DNA mutation in colorectal tumours and explained by high level of reactive oxygen species (ROS) in mitochondria (Polyak et al., 1998) . Similarly, Smad gene mutations observed here may be caused by high levels of ROS in the precursor cells of these tumours.
Previous studies showed that Smad4 is altered in a signi®cant portion of pancreatic and common bile duct cancers (Hanh et al., 1998) and a minority of colorectal cancers (Eppert et al., 1996; Takagi et al., 1996) but rarely in other tumours . Smad2 gene alterations are also limited to a small fraction of colorectal and lung cancers (Riggins et al., 1996 (Riggins et al., , 1997 Uchida et al., 1996. Our data suggest that, Smad2 and Smad4 gene mutations may contribute to a fraction of HCCs. Low prevalence of these alterations may be explained with genetic heterogeneity of HCC (Unsal et al., 1994) . Indeed, Kawate et al. (1999) reported very recently that mutations of TGFb-receptor II, Smad2 and Smad4 mutations are rare in HCCs from Japan. In addition, Smad mutations in HCC could occur at late stages during tumor progression. In an animal model of compound heterozygosity for APC and Smad4, inactivation of Smad4 gene resulted in the malignant progression of the intestinal and colonic polyps initiated by LOH in the APC gene. This observation suggested the inactivation of Smad4 as a late event in carcinogenesis (Takaku et al., 1998) .
In conclusion, we identi®ed Smad gene mutations in HCC at a frequency of *10%. The occurrence of these mutations provides evidence that TGFb pathway is altered in HCC. In conformation to our hypothesis, TGFb itself was identi®ed as a new form of tumour suppressor for liver and lung cancers in mice heterozygous for deletion of the TGFb gene (Tang et al., 1998) . However, the low frequency of Smad gene mutations in human HCC also suggest that other genes of TGFb pathway may also be alterated in these tumours.
Materials and methods

Tumour samples and cell lines
We analysed a total of 35 pair of DNA samples isolated from HCC and non-tumour liver tissues from patients living in dierent geographical regions including Mozambique (n=7), South Africa (n=11), China (n=8), Japan (n=6) and Germany (n=3). Characteristics of these tumours and methods for DNA isolation have been described previously (Unsal et al., 1994) . We also analysed six established hepatoma cell lines (HepG2, Huh7, Mahlavu, PLC/PRF/5, Hep3B and Focus). Genomic DNA from cell lines was isolated as described (Unsal et al., 1994) . Total RNA from cell lines were isolated using Ultraspect RNA extraction kit (Biotecx) according to the manufacturer's directions.
RT ± PCR
cDNAs were synthesised by MMLV reverse transcriptase (SuperScript TM , Gibco) using oligo (dT) 12 ± 18 primers. The entire coding region of Smad2 and Smad4 genes were ampli®ed using primers indicated in Table 2 . PCR was performed in 50 ml reaction mixture containing 1 ml of the complementary DNA mix, 16Taq buer (MBI), 1.5 mM MgCl 2 , 1 unit of Taq DNA polymerase, 20 pmol of each primer and 10 mM each of dNTPs. PCR conditions consisted of 35 cycles of denaturation at 948C for 60 s, annealing at temperatures varying between 55 ± 568C (see Table 2 for primer sequences and annealing temperatures) for 30 s, followed by an extension at 728C for 90 s. The ®nal cycle included an additional 3 min extension at 728C.
SSCP analysis
PCR was performed using 50 ng genomic DNA, 16Taq buer (MBI), 1.5 mM MgCl 2 , 1 unit of Taq DNA polymerase, 20 pmol of each primer, 40 mM each of dNTPs, 2 mCi [a-32 P]dATP (1000 Ci/mmol, Amersham) in a ®nal volume of 25 ml. PCR conditions consisted of 30 cycles of denaturation at 948C for 45 s, annealing at temperatures varying between 50 ± 608C (see Table 2 for primer sequences and annealing temperatures) for 30 s, followed by an extension at 728C for 1 min. The ®nal cycle included an additional 3 min extension at 728C. SSCP analysis of PCR products was done at both 48C and room temperature, on 10% of acrylamide gel with or without glycerol as well as on MDE gels (FMC Bioproducts). Gels were mounted on a 3M Whatman paper, dried and visualised by autoradiography.
Sequence analysis
For the analysis of tumour PCR products, aberrantly migrating radioactive bands were recovered from SSCP gels in order to enrich for mutant DNA fragments before sequencing. Selected bands were cut with a razor blade, eluted into TE and reampli®ed as described, except that [a-32 P]dATP was omitted. Non-tumour PCR products were analysed directly following non-radioactive PCR amplification. PCR products were puri®ed using Quick PCR puri®cation kit (Qiagen). For sequencing reactions, dye terminator cycle sequencing ready reaction kit (ABI Prism) was used. Reaction products were then analysed using the ABI Prism 377¯uorescent DNA sequencer (Perkin Elmer). Identi®ed mutations were con®rmed by DNA sequencing of independent PCR products after cloning into pGEM-T plasmid (Promega).
